Research Article
Impact of SNPs/Haplotypes of IL10 and IFNG on the Development of Diffuse Large B-Cell Lymphoma
Table 1
Clinical and epidemiological characteristics of patients with diffuse large B-cell non-Hodgkin’s lymphoma (
) and controls (
).
| | Characteristics | Patients | Controls | |
| | Age () | | | 0.01 | | Gender (%) | | | | | Female | 57 (50.9) | 109 (49.3) | NS | | Male | 55 (49.1) | 112 (50.7) | NS | | Clinical stage (%) | | | | | I-II | 44 (39.2) | | | | III-IV | 68 (60.7) | | | | LDH (%) | | | | | ≥Normal | 51 (45.5) | | | | Unknown | 8 (7.1) | | | | IPI (%) | | | | | Low and intermediate-low | 70 (62.5) | | | | Intermediate-high and high | 33 (29.5) | | | | Unknown | 9 (8.0) | | | | Treatment (%) | | | | | R-CHOP | 101 (90.2) | | | | Others | 8 (7.1) | | | | Not treated | 3 (2.7) | | | | Response to treatment with R-CHOP (%) | | | | | Complete remission | 72 (71.2) | | | | Progression of disease | 4 (4.0) | | | | Relapse | 4 (4.0) | | | | Death | 17 (16.8) | | | | Lost to follow-up | 4 (4.0) | | |
|
|
NS = not significant; LDH = lactate dehydrogenase; IPI = international prognosis index; R-CHOP = Rituximab—Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
|
